ibalizumab
ibalizumab is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including TROGARZO. Available dosage forms: liquid, injection, solution, solution.
Drug Details
- Generic Name
- ibalizumab
- Brand Names
- TROGARZO
- Application Number
- BLA761065
- Sponsor
- SAMSUNG BIOLOGICS Co., Ltd.
- NDC Codes
- 3
- Dosage Forms
- LIQUID, INJECTION, SOLUTION, SOLUTION
- Routes
- INTRAVENOUS
- Active Ingredients
- IBALIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. TROGARZO, a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.